19 Feb 2015 07:00
BTG plc launches a Level 1 ADR programme
London, UK, 19 February, 2015: BTG plc (LSE:BTG), the specialist healthcare company, today announces the launch of a sponsored Level 1 American Depositary Receipt (ADR) programme.
The ADR programme will be open for deposits from 9 a.m. (EST) today. The ADR's CUSIP is 05581D107, and the ADR ticker symbol is BTGYY. Each ADR represents one BTG ordinary share.
Andy Burrows, Vice President, Corporate and Investor Relations at BTG commented:
"Establishing a sponsored ADR offers U.S. investors a more structured platform on which to invest in our company. This step will raise our profile with the key U.S. investment base and supports our investor outreach programme."
J.P. Morgan will act as the depositary bank for the ADR programme. For market information on ADRs go to J.P. Morgan's web site: www.adr.com.
For further information contact:
BTG FTI Consulting
Andy Burrows, VP Corporate & Investor Relations Ben Atwell/Simon Conway
+44 (0)20 7575 1741; Mobile: +44 (0)7990 530 605 +44 (0)20 3727 1000
Stuart Hunt, Investor Relations Manager J.P. Morgan
+44 (0)20 7575 1582; Mobile: +44 (0)7815 778 536 Charles Heming
+44 (0)20 7134 5566
About BTG
BTG is a growing international specialist healthcare company bringing to market innovative products in specialist areas of medicine to better serve doctors and their patients. We have a portfolio of Interventional Medicine products to advance the treatment of liver tumours, severe blood clots, varicose veins and advanced emphysema, and Specialty Pharmaceuticals that help patients overexposed to certain medications or toxins. Inspired by patient and physician needs, BTG is investing to expand its portfolio to address some of today's most complex healthcare challenges. To learn more about BTG, please visit: www.btgplc.com.